

LY2334737

Catalog No: tcsc1815



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

892128-60-8

Formula:

$C_{17}H_{25}F_2N_3O_5$

Pathway:

Cell Cycle/DNA Damage

Target:

Nucleoside Antimetabolite/Analog

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

389.39

Product Description


LY2334737 is an orally available prodrug of gemcitabine which is a nucleoside analog used as chemotherapy.

IC50 Value:

Target: Nucleoside analog

in vitro: Five cell lines that express CES2 responded to LY2334737 treatment. LY2334737 was less cytotoxic to a SK-OV-3 CES2 knockdown than parental cells. The drug response of CES2-transfected HCT-116 cells correlated with CES2 expression level. Bystander studies showed statistically greater PC-3-GFP growth inhibition by LY2334737 when cells were cocultured with CES2 and not mock transfectants [1].

in vivo: Oral treatment of xenograft models with 3.2 mg/kg LY2334737 once a day for 21 days showed greater tumor growth inhibition of CES2 transfectant than the mock transfectant ($P \leq 0.001$) [1]. The MTD was 40 mg LY2334737. Fatigue was the most frequent DLT for LY2334737 monotherapy (4 patients) followed by elevated transaminase levels (2 patients), both observed at the 40- to 50-mg dose levels. Among the 10 patients in the combination arm, 2 had DLTs at the 40-mg dose level. These were fatigue and elevated liver enzyme levels [2]. Metronomic LY2334737 administration caused increased blood flow in luciferase-tagged LM2-4 tumor xenografts, and this effect, readily measured using contrast micro-ultrasound, coincided with a relative increase in tumor bioluminescence [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!